pocketful logo
Lyka Labs Ltd logo

Lyka Labs Ltd

NSE: LYKALABS BSE: 500259

₹54.95

(4.43%)

Sat, 21 Mar 2026, 04:36 pm

mtf coin illustrationMTF 5x

Lyka Labs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    197.33

  • Net Profit

    7.93

  • P/B

    3.48

  • Sector P/E

    31.32

  • P/E

    45.07

  • EV/EBITDA

    19.69

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    12.90

  • RONW (Industry)

    12.30

  • ROE

    5.25

  • ROCE

    6.62

  • Debt/Equity

    0.55

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    28.33

  • Interest Cover

    5.90

Analysis

all

thumbs up icon

Pros

  • Whilst loss making Lyka Labs has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -11.3% per year.
  • Whilst loss making Lyka Labs has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Kunal's remuneration is about average for companies of similar size in India.
  • NSEI:LYKALABS is up 20.2% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
  • NSEI:LYKALABS is up 20.2% outperforming the market in India which returned 8% over the past month.
thumbs up icon

Cons

  • Unable to evaluate Lyka Labs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lyka Labs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Lyka Labs's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Debt is not well covered by operating cash flow (3.8%, less than 20% of total debt).
  • Lyka Labs has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters58.1658.1658.1658.1658.10
FII0.170.170.160.230.15
DII0.670.670.670.670.67
Public41.0041.0041.0240.9441.07
Government00000

Read More

Technical Analysis

RSI

37.60

MACD

-4.09

50 DMA

66.90

200 DMA

90.03

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic92.7779.1270.7365.4757.0851.8238.17
Fibonacci79.1273.9070.6865.4760.2557.0351.82
Camarilla66.1064.8563.6065.4761.1059.8558.60

Pivots Level: Classic

R3

+27.30

92.77

R2

+13.65

79.12

R1

+5.27

70.73

65.47
65.47
Pivot Point
LTP: 54.95

S1

-8.38

57.08

S2

-13.65

51.82

S3

-27.30

38.17

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    55.14

  • 20-EMA

    58.15

  • 30-EMA

    60.85

  • 50-EMA

    65.23

  • 100-EMA

    73.78

  • 200-EMA

    86.36

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 Jan 2026board-meetingsQuarterly Results
12 Nov 2025board-meetingsQuarterly Results, Half Yearly Results, EGM, Change in Registered Address
08 Jul 2025agm
31 Jan 2025egm
15 Jul 2024agm
01 Jul 2024agmAnnual General Meeting02 Aug 2024
18 Jan 2024egm
10 Jul 2023agm
21 Jun 2023agmAnnual General Meeting24 Jul 2023
21 Jan 2023egm

Read More

Peer Comparison

Lyka Labs Ltd logo

Lyka Labs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Lyka Labs Ltd About

Lyka Labs is engaged in the business of pharmaceutical and related activities, including research.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1976

Headquarters

CEO

Babulal Jain

Employees

Contact

Website icon

Website

http://www.lykalabs.com

Email icon

Email

investorredressal@lykalabs.com; enquiry@lykalabs.c

Phone icon

Phone

91-02646-221422/220549

Location icon

Location

4801/B & 4802/A, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002

Read More

Lyka Labs Ltd Company History

YearHistory
2012
  • The company updated its email ID
2014
  • Mr Yogesh B Shah was appointed as Chief Finance Officer
2016
  • Lyka Healthcare Limited launched two domestic marketing divisions
2017
  • Amalgamation of Lyka Healthcare Ltd with Lyka Labs Ltd
2021
  • Merger of Lyka Exports Limited with Lyka Labs Limited

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPSell198593164.1905 Sept 2024
GRAVITON RESEARCH CAPITAL LLPBuy198593164.0805 Sept 2024
GRAVITON RESEARCH CAPITAL LLPSell190740147.9222 Aug 2024
GRAVITON RESEARCH CAPITAL LLPBuy190740147.8422 Aug 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBuy230144154.2521 Aug 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDSell183892145.5321 Aug 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDSell250000154.2821 Aug 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy183892145.3721 Aug 2024
QUANT MUTUAL FUND QUANT SMALL CAP FUNDSell150000101.9302 Jun 2023
PRABHULAL LALLUBHAI PAREKHBuy18506191.9726 May 2023

Read More

Lyka Labs Ltd News

Lyka Labs Gets NCLT Approval for Merger with Lyka Exports

NCLT Ahmedabad approves scheme of amalgamation between Lyka Exports Limited and Lyka Labs Limited with appointed date of April 01, 2022. Company to file INC-28 form within 30 days.

17 Mar 2026

companies

Lyka Labs Cost Auditors Resign for FY 2025-26

Lyka Labs announces resignation of cost auditors Messrs Rajaram Madhav Walavalkar & Co. for FY 2025-26 due to other professional commitments, effective March 5, 2026.

06 Mar 2026

stocks

Lyka Labs Q3FY26 Results: Revenue Drops 6.6% YoY

Lyka Labs reported Q3FY26 revenue of ₹3,072.79 lakhs, down 6.6% YoY. Standalone net profit fell to ₹27.99 lakhs from ₹269.85 lakhs in Q3FY25. Nine-month performance shows revenue decline of 10.9% YoY.

29 Jan 2026

co actions results

NCLT Grants Final Opportunity to Income Tax Counsel in Lyka Labs Merger Case

The National Company Law Tribunal (NCLT) has given a final chance for Income Tax counsel to respond to Lyka Labs' merger application, with no opposition received from the Income Tax Department so far. The NCLT has reserved its order on the merger application while awaiting the final response from tax authorities.

05 Dec 2025

corporate action

Lyka Labs Reports Net Loss of Rs 72.68 Lakhs in Q2 FY26, Defers Registered Office Relocation Decision

Lyka Labs Limited reported a net loss of Rs 72.68 lakhs for the quarter ended September 30, 2025, compared to a profit of Rs 7.20 lakhs in the same quarter last year. The pharmaceutical company's revenue declined to Rs 2,862.64 lakhs from Rs 3,013.83 lakhs year-on-year. The Board approved the quarterly financial results and decided to defer the decision on shifting the registered office. The company recognized an Expected Credit Loss provision of Rs 484.03 lakhs for international trade receivables during the quarter. Additionally, 1,08,570 preference shares worth Rs 108.57 lakhs were redeemed. The earnings per share stood at negative Rs 2.02 compared to positive Rs 0.69 in the previous year quarter.

13 Nov 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800